Lei et al. reveal that H19 promotes gefitinib resistance in NSCLC through exosome packaging with the assistance of hnRNPA2B1, and propose that exosomal H19 may be a promising target for NSCLC treatment 111. This evidence concerns the gene HNRNPA2B1 and non-small cell lung carcinoma.